Guardant Health (GH) Stock Price
Guardant Health Price
Over the last 9 years Guardant Health grew revenue by 52.3% annually, reaching 978.12 M USD. For Guardant Health, the net margin of -42.6% is up versus -109.3% a few years ago. The consensus 12-month price target for Guardant Health is 195.00 USD, about 24.1% above where the stock trades today. Of 36 analysts, 33 rate the stock a buy — an overall Buy consensus.
Guardant Health stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Guardant Health business model & stock analysis
Frequently asked questions about Guardant Health
The main competitors of Guardant Health Inc in the market include companies such as Foundation Medicine, Exact Sciences Corporation, and Illumina Inc.
The business model of Guardant Health Inc. revolves around precision oncology and liquid biopsy. As a leading precision oncology company, Guardant Health develops and commercializes blood tests that can detect and monitor cancer. By analyzing the genetic alterations in circulating tumor DNA, Guardant Health enables oncologists to make more informed treatment decisions for their patients. The company's comprehensive liquid biopsy platform, including their flagship product Guardant360, provides a non-invasive alternative to traditional tissue biopsies. With their commitment to advancing cancer care, Guardant Health Inc. aims to improve patient outcomes through their innovative molecular diagnostics and therapeutic development solutions.
Guardant Health Inc is primarily active in the healthcare industry.
Guardant Health Inc. is a leading precision oncology company specializing in blood-based cancer tests. Founded in 2012, Guardant Health has rapidly grown to become a prominent player in the field of liquid biopsy. The company's breakthrough technology, Guardant360, enables comprehensive genomic profiling of solid tumors through a simple blood draw, facilitating personalized treatment decisions for cancer patients. With an extensive database of over 120,000 patients, Guardant Health Inc. is revolutionizing cancer diagnostics and therapy selection. Guardant Health is committed to advancing precision oncology and improving patient outcomes through its innovative genomic testing solutions.
Some significant milestones achieved by Guardant Health Inc include the successful completion of their initial public offering (IPO) in October 2018, generating over $235 million in funding. Additionally, the company's liquid biopsy test, Guardant360, received breakthrough device designation from the U.S. FDA in 2018, highlighting its potential impact in cancer diagnostics. Guardant Health Inc also expanded its global presence by establishing partnerships with several pharmaceutical companies and collaborating with research institutions. These achievements demonstrate Guardant Health Inc's growth as a leader in precision oncology, offering innovative solutions and advancing cancer care.
Guardant Health Inc is primarily present in the United States.
Guardant Health Inc represents values of innovation, precision, and compassion in the field of comprehensive cancer care. As a leading precision oncology company, Guardant Health is committed to transforming cancer treatment through advanced diagnostics and therapeutics. With their liquid biopsy technology, they aim to provide personalized and non-invasive genomic profiling, aiding in early cancer detection and treatment decisions. Guardant Health's corporate philosophy revolves around collaboration and empowerment, as they strive to improve patient outcomes and ease the burden of cancer. By combining cutting-edge technology with compassionate care, Guardant Health Inc epitomizes a commitment to revolutionizing cancer care for a better future.
Analysts currently set an average price target of 188.80 USD for the Guardant Health stock (median: 195.00 USD), implying +20.2 % versus the latest price. The consensus is based on 36 analyst ratings.
36 analysts currently rate the Guardant Health stock: 33 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Guardant Health to generate revenue of 1.36 B USD and earnings per share of -3.25 USD.
Converted at the current exchange rate, the Guardant Health share trades at 140.43 EUR (157.10 USD).
The Guardant Health share (GH) is listed on 5 stock exchanges, including: NASDAQ (GH), XETRA (5GH.DE), Frankfurt (5GH.F), München (5GH.MU), Düsseldorf (5GH.DU).
Guardant Health Inc. is a leading company in the field of liquid biopsy and cancer early detection. The company offers innovative solutions and technologies for cancer prevention, diagnosis, and therapy. Guardant Health has two different business units: Guardant360 and GuardantOMNI. Both divisions differ in their target audience and product portfolio. Guardant360 is a blood test that captures the DNA profile of tumor cells, thereby identifying the genetic fingerprint of cancer cells. This allows for more precise and faster diagnosis. The technology of Guardant360 is used by doctors and oncologists to analyze the genetic profiles of tumor cells in real-time and develop the best possible therapy for the patient. GuardantOMNI is a comprehensive cancer genomic test that covers over 500 genes, enabling an accurate diagnosis. GuardantOMNI is used by pharmaceutical companies to develop personalized therapies and drugs. Guardant Health is committed to advancing precision medicine in the field of cancer diagnostics and therapy. By using liquid biopsy technologies, doctors and oncologists can make accurate diagnoses and offer targeted therapy. Guardant Health has also partnered with renowned pharmaceutical companies such as Merck, Bristol-Myers Squibb, and Amgen to develop personalized therapies. In addition, the company has conducted its own clinical study on cancer early detection, and further studies are planned. The business model of Guardant Health is based on selling its products and solutions to medical facilities such as hospitals, laboratories, and oncologists. The company also generates revenue through partnerships with pharmaceutical companies and participation in clinical trials. Overall, Guardant Health is a company with a promising business model based on the use of liquid biopsy technologies. The company aims to revolutionize cancer diagnostics and therapy and offer personalized medicine. The wide portfolio of solutions and products from Guardant Health allows it to cater to the needs of doctors, oncologists, and pharmaceutical companies.
The expected revenue of Guardant Health is 1.36 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Guardant Health is -418.42 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Guardant Health is currently -48.30. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Guardant Health stock.
The price-to-sales ratio (P/S) of Guardant Health is currently 14.89. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Guardant Health stock.
The Eulerpool Quality Score for Guardant Health is 5/10.
The ISIN of Guardant Health is US40131M1099. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Guardant Health is A2N5RY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Guardant Health is GH. The ticker symbol is used to trade Guardant Health shares on the stock exchange.
Guardant Health stock
Guardant Health Peer Group
Guardant Health Ticker
Guardant Health FIGI
All fundamentals and in-depth analysis of Guardant Health
Our stock analysis for Guardant Health stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Guardant Health. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.